AGIO (Agios) רווח למניה בארבעת הרבעונים האחרונים

Agios Pharmaceuticals (AGIO) is developing precision bioengineering to treat rare blood pathologies. The rolling year net income per share trend on this GURU.Markets chart confirms this trajectory, and the value of 9.00 shows the latest figure. This requires strict control over drug delivery; however, reliance on a single product and R&D risks are constraining the pace of reaching profitability.
AGIO (Agios Pharmaceuticals): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Strategic partnerships between Agios Pharmaceuticals (AGIO) and pharmaceutical behemoths and research centers specializing in rare diseases directly drive profit dynamics. By analyzing the trailing twelve months (TTM) earnings per share (EPS) growth rate, investors can track the percentage change in net income over a rolling year, enabling an assessment of commercialization efficiency and the impact of fundamental successes on the issuer's market capitalization.